Related references
Note: Only part of the references are listed.Lipid signaling in adipose tissue: Connecting inflammation & metabolism
Mojgan Masoodi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2015)
Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension
Masato Furuhashi et al.
HYPERTENSION RESEARCH (2015)
Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity
Meric Erikci Ertunc et al.
JOURNAL OF LIPID RESEARCH (2015)
FABP4 is Secreted from Adipocytes by Adenyl Cyclase-PKA- and Guanylyl Cyclase-PKG-Dependent Lipolytic Mechanisms
Tomohiro Mita et al.
OBESITY (2015)
Ectopic Expression of Fatty Acid-Binding Protein 4 in the Glomerulus Is Associated with Proteinuria and Renal Dysfunction
Marenao Tanaka et al.
NEPHRON CLINICAL PRACTICE (2014)
Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population
Takahiro Fuseya et al.
CARDIOVASCULAR DIABETOLOGY (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
Urinary Excretion of Fatty Acid-Binding Protein 4 is Associated with Albuminuria and Renal Dysfunction
Yusuke Okazaki et al.
PLOS ONE (2014)
Capillary Endothelial Fatty Acid Binding Proteins 4 and 5 Play a Critical Role in Fatty Acid Uptake in Heart and Skeletal Muscle
Tatsuya Iso et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats
Nattayaporn Apaijai et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
Adipocyte Lipid Chaperone aP2 Is a Secreted Adipokine Regulating Hepatic Glucose Production
Haiming Cao et al.
CELL METABOLISM (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
Noriko Satoh-Asahara et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Circulating Levels of Fatty Acid-Binding Protein Family and Metabolic Phenotype in the General Population
Shutaro Ishimura et al.
PLOS ONE (2013)
Elevated Circulating Adipocyte-Fatty Acid Binding Protein Levels Predict Incident Cardiovascular Events in a Community-Based Cohort: A 12-Year Prospective Study
Wing Sun Chow et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Elevation of Fatty Acid-Binding Protein 4 Is Predisposed by Family History of Hypertension and Contributes to Blood Pressure Elevation
Hideki Ota et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease A 10-year Prospective Study
Maximilian von Eynatten et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells
Gemma Aragones et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Vanita R. Aroda et al.
CLINICAL THERAPEUTICS (2012)
RNA Interference-Based Silencing Reveals the Regulatory Role of Fatty Acid-Binding Protein 4 in the Production of IL-6 and Vascular Endothelial Growth Factor in 3T3-L1 Adipocytes
Kazuaki Kajimoto et al.
ENDOCRINOLOGY (2012)
Sitagliptin Exerts an Antinflammatory Action
Antoine Makdissi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression
Joana Rosmaninho-Salgado et al.
PEPTIDES (2012)
Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans
Wei Gao et al.
DRUG METABOLISM AND DISPOSITION (2012)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Impact of Glycemic and Blood Pressure Variability on Surrogate Measures of Cardiovascular Outcomes in Type 2 Diabetic Patients
Alessandra Di Flaviani et al.
DIABETES CARE (2011)
Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients
Toru Miyoshi et al.
HEART AND VESSELS (2011)
Serum Fatty Acid-Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease
Masato Furuhashi et al.
PLOS ONE (2011)
Lipid Chaperones and Metabolic Inflammation
Masato Furuhashi et al.
INTERNATIONAL JOURNAL OF INFLAMMATION (2011)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Adipocyte Fatty Acid-Binding Protein Suppresses Cardiomyocyte Contraction A New Link Between Obesity and Heart Disease
Valeria Lamounier-Zepter et al.
CIRCULATION RESEARCH (2009)
Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells
Harun Elmasri et al.
FASEB JOURNAL (2009)
Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes
Anna Cabre et al.
JOURNAL OF LIPID RESEARCH (2008)
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Masato Furuhashi et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria
Anna Cabre et al.
CLINICAL CHEMISTRY (2008)
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat-fed mice
Benjamin J. Lamont et al.
DIABETES (2008)
Genomic changes in regenerated porcine coronary arterial endothelial cells
Mary Y. K. Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Serum adipocyte fatty acid-binding protein as a new biomarker, predicting the development of type 2 diabetes - A 10-year prospective study in a Chinese cohort
Annette W. K. Tso et al.
DIABETES CARE (2007)
Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis
D. C. Y. Yeung et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia
M. Karpisek et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
Masato Furuhashi et al.
NATURE (2007)
Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome - A 5-year prospective study
Aimin Xu et al.
CIRCULATION (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome
AM Xu et al.
CLINICAL CHEMISTRY (2006)
Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis
L Makowski et al.
NATURE MEDICINE (2001)
Share Paper
